Relmada Therapeutics is down 30% since two insiders disclosed purchases
- Insider
- Sergio Traversa
- Role
- Chief Executive Officer
- Company
- Relmada Therapeutics, Inc. (RLMD)
- Transaction
- Buy
- Shares
- 100,000
- Amount
- $410K
- Trade date
- Sep 10, 2026
- Filed
- Sep 11, 2026, 1 day after the trade
- Source
- SEC Form 4 ↗
Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, Inc., bought 100,000 shares at $4.10 on September 10, 2026, for a total of $410K. The purchase was reported to the SEC on September 11, 2026, 1 day after the trade. One other insider, Shenouda Maged, also disclosed a purchase on September 10, 2026.
Relmada closed at $3.16 on October 19, 2026, 30.1% below the first close after the purchase ($4.52 on Sep 11, 2026). Measured from the first close after the filing ($4.44 on Sep 14, 2026), the decline is 28.8%. No sales by Sergio Traversa have been reported since.
RLMD +4.1% on the day, close Oct 30
Since purchase−30.1%$4.52 → $3.16
Since filing−28.8%$4.44 on Sep 14 → $3.16
Purchase$410K100,000 shares on Sep 10, 2026
Days since purchase39No sales by this filer since
Price since the purchase
Daily close · USD0%
−30%
Sep 11 · first close $4.52Oct 19 · $3.16
PurchaseFirst close below −30%